Tumor Blood Testing Market on Track for Strong Growth, Estimated to Grow at 13.2% CAGR Through 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Tumor Blood Testing Market Through 2025?
The market size for tumor blood testing has seen significant expansion in recent years. Projections show that it will rise from $5.27 billion in 2024 to $5.98 billion in 2025, signifying a compound annual growth rate (CAGR) of 13.5%. The noteworthy growth observed during the historic period is linked to factors such as the surge in genomics and proteomics research, heightened patient expectations for swift test outcomes, the development of targeted therapies that necessitate companion diagnostics, an increasing trend towards decentralized diagnostics, and a prevalent patient inclination towards home-based sample gathering.

What's the Projected Size of the Global Tumor Blood Testing Market by 2029?
Anticipated swift expansion in the coming years is projected for the tumor blood testing market, which is set to rise to $9.83 billion by 2029, showing a compound annual growth rate (CAGR) of 13.2%. Factors contributing to this advancement throughout the prediction period include a surge in point-of-care testing solutions usage, growing clinical validation of innovative blood tests, enhanced government and private funding for cancer research, increased availability of high-sensitivity tumor biomarkers, and a growing patient preference for less intrusive procedures. Key trends for the forecast period encompass innovations in multi-cancer early detection (MCED) tests, progress in companion diagnostics, advancements in synthetic biology applications in diagnostics, employment of blockchain for data security in diagnostics, and the incorporation of robotics in lab processes.

View the full report here:
https://www.thebusinessresearchcompany.com/report/tumor-blood-testing-global-market-report

Top Growth Drivers in the Tumor Blood Testing Industry: What's Accelerating the Market?
The rising occurrence of cancer is anticipated to propel the growth of the tumor blood testing market in future years. Factors such as an aging population and exposure to risk elements like poor diet, smoking, and pollution are leading to more cases of cancer, thus escalating the need for early detection techniques. Tumor blood tests offer a less invasive method to spot cancer before symptoms begin to show by identifying biomarkers present in the bloodstream. This facilitates prompt diagnosis, speedy treatment, enhanced patient results, and persistent surveillance of disease advancement and the effectiveness of treatment. For example, records from the National Cancer Institute (a US government agency) in May 2024 indicate that, as of January 2022, there were approximately 18.1 million cancer survivors in the US, and this figure is projected to escalate to 26 million by 2040. Consequently, the escalating occurrence of cancer is spurring the growth of the tumor blood testing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28343&type=smp

What Trends Will Shape the Tumor Blood Testing Market Through 2029 and Beyond?
Leading enterprises in the tumor blood testing market are focusing on the creation of innovative technology, like non-invasive liquid biopsy technologies. These advancements aim to improve the early detection of cancer, track the response to treatment, and examine disease progression more effectively. These non-invasive liquid biopsy technologies are diagnostic tests that identify and scrutinize cancer-related biomarkers present in bodily fluids, acting as a safer and more practical replacement for conventional tissue biopsies. In February 2024, for example, Delfi Diagnostics, an American biotechnology company, teamed up with Immunocore Holdings plc, a British biotech firm, to unveil the DELFI-Tumor Fraction (DELFI-TF) assay, a blood test designed for monitoring cancer. The test investigates cell-free DNA (cfDNA) fragments present in the bloodstream to evaluate tumor burden and treatment response. This fragmentome-based liquid biopsy presents a non-invasive, cost-efficient alternative to traditional approaches, requiring minimum plasma and delivering results in a fortnight.

What Are the Main Segments in the Tumor Blood Testing Market?
The tumor blood testing market covered in this report is segmented as

1) By Test Type: Circulating Tumor Cells (CTC) Tests, Circulating Tumor DNA (CtDNA) Tests, Exosome-Based Tests, Other Test Types
2) By Technology: Polymerase Chain Reaction (PCR)-Based Testing, Next-Generation Sequencing, Microarray-Based Testing, Mass Spectrometry, Immunoassays
3) By Cancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Melanoma
4) By Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring
5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users

Subsegments:
1) By Circulating Tumor Cells Tests: Isolation Of Tumor Cells, Enumeration Of Tumor Cells, Characterization Of Tumor Cells
2) By Circulating Tumor DNA Tests: Mutation Detection Of Tumor DNA, Methylation Analysis Of Tumor DNA, Copy Number Variation Analysis Of Tumor DNA, Fragmentation Analysis Of Tumor DNA
3) By Exosome-Based Tests: Protein Profiling Of Exosomes, RNA Profiling Of Exosomes, Lipid Profiling Of Exosomes, Surface Marker Analysis Of Exosomes
4) By Other Tests: Circulating RNA Tests, Tumor Educated Platelet Tests, Protein Biomarker Panels, Multiomics Blood Tests, Immuno Oncology Biomarker Tests

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28343&type=smp

Which Top Companies are Driving Growth in the Tumor Blood Testing Market?
Major companies operating in the tumor blood testing market are Bio-Techne Corporation, Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Natera Inc., Myriad Genetics Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Personal Genome Diagnostics Inc., Exosome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems S.p.A.

Which Regions Will Dominate the Tumor Blood Testing Market Through 2029?
North America was the largest region in the tumor blood testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tumor blood testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28343

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.